First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis.
Encapsulating peritoneal sclerosis (EPS) is a rare but serious life-threatening complication in peritoneal dialysis patients. At present, there is no evidence-based standard therapy for EPS. Tamoxifen has been used and shown good results in non-HIV peritoneal dialysis patients with EPS. We report a case of a patient with HIV treated with antiretroviral therapy (zidovudine, lamivudine and saquinavir) for several years. He had end-stage renal disease and was treated with continuous ambulatory peritoneal dialysis (CAPD). After 11 years on CAPD, he developed EPS and was treated successfully with tamoxifen in combination with corticosteroids. No adverse effects were observed and no changes were noted in CD4 counts or HIV viral load during this therapy. These findings suggest that tamoxifen can be safely given to HIV patients with peritoneal dialysis-related EPS. Nevertheless, caution is required as tamoxifen could interact with certain antiretroviral agents.
Mesquita
M
M
Department of Internal Medicine and Nephrology-Dialysis Division, Brugmann University Hospital (Free University of Brussels), Brussels, Belgium. maria.mesquita@chu-brugmann.be
Guillaume
M P
MP
Dratwa
M
M
D019380:Anti-HIV Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010532:Peritoneal Diseases / Q000188:drug therapy* / Q000209:etiology; D019258:Saquinavir / Q000627:therapeutic use; D012598:Sclerosis / Q000188:drug therapy* / Q000209:etiology; D013629:Tamoxifen / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use